^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MCARH125
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Memorial Sloan-Kettering Cancer Center
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/14/2023
Initiation :
06/20/2022
Primary completion :
06/20/2024
Completion :
06/20/2024
SDC1
|
MCARH109 • MCARH125
Share
